Approximately 30 to 40% of patients with advanced lung cancer will develop bone metastases
in the course of their disease, resulting in a significant negative impact on both morbidity …

Lung cancer is a highly heterogeneous disease often driven by well-characterized driver
mutations. Although the best studied are common alterations in the epidermal growth factor …

… This could be explained by the short overall survival of advanced lung cancer patients (183
days in placebo group and 203 in zoledronic acid group, p=0.623 in this analysis) entered …

Background In MONALEESA-2, ribociclib plus letrozole showed improved progression-free
survival compared with letrozole alone as first-line treatment for postmenopausal patients …

Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to
immunotherapy. BR.36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of molecular …

… likely to have received prior platinum-based chemotherapy (P .0001) and were more likely
to be receiving erlotinib as second-line treatment (P .08) For patients who received one line of …

… P. Wheatley-Price reports personal fees from Amgen, Janssen, Sanofi-Aventis, Novartis,
Jazz Pharmaceuticals, Bayer HealthCare, BMS, Merck, Roche, AstraZeneca, EMD Serono, and …

Background: Some non-small-cell lung cancer (NSCLC) surgical series have indicated that
the positive prognostic effect of female sex is limited to patients with adenocarcinoma. We …

… All statistical tests were 2-sided and considered statistically significant at α < 0.05, however
we suggest caution in interpretation of p-value bigger than 0.05 as tests are not powered …